BESREMi, illustration of injection pen form (not a photo of the actual pack)

Illustrative image.

BESREMi

Ropeginterferon Alfa-2b

Prescription required

$22710.00

250MCG/0.5ML · 6 × 1 pen · 3 months supply

BrandBranded medicine· By PharmaEssentia

$7570.00 per month

How long a supply?

1 month$7570.00 a month
3 months$7570.00 a month
Supplied from Israel

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Annual cost

$98410a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningRisk of serious disorders

Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy.

Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or worsening signs or symptoms of the above disorders.

Read this with the rest of the clinical information

About BESREMi

Overview

BESREMi contains ropeginterferon alfa-2b, a type of interferon, and is supplied as a prefilled pen for injection under the skin. It is used to treat adults with essential thrombocythemia or polycythemia vera. It works by attaching to interferon receptors on cells in the bone marrow and triggering signals that change cell activity, although its treatment effects are not fully understood.

What it treats

- Essential thrombocythemia in adults. - Polycythemia vera in adults.

Safety information

Side effects

Common side effects reported in patients with polycythemia vera include flu-like illness, joint pain, tiredness, itching, inflammation of the nose and throat, and muscle and bone pain. In patients with essential thrombocythemia, common side effects include raised liver enzymes, anemia, fever, increased levels of a protein called beta-2 microglobulin in the urine, bacterial infections, itching and weight loss. Contact a doctor promptly about depression or other mood changes, eye symptoms, or new or worsening health problems during treatment. Seek immediate medical help for suicidal thoughts or an allergic reaction. Serious risks include hormone disorders, heart and circulation problems, blood cell disorders and bleeding, inflammation of the pancreas or colon, lung problems, eye damage, raised blood fats, liver or kidney damage, dental and gum problems, and serious skin reactions. Blood tests and other monitoring are needed because some problems may not cause noticeable symptoms. Do not drive or use machinery if you experience dizziness, sleepiness or hallucinations. BESREMi can harm an unborn baby; contact your doctor if you become pregnant during treatment.

FDA boxed warning

Risk of serious disorders

Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy.

Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or worsening signs or symptoms of the above disorders.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek medical attention immediately for new or worsening depression or thoughts of suicide. - Get immediate medical help for an allergic reaction. - Seek prompt medical attention for new or worsening eye symptoms. - Get medical attention immediately for hallucinations, seeing or hearing things that are not there. Do not drive or use machinery.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not use BESREMi if you: • Have or have had a severe psychiatric disorder, particularly severe depression, suicidal thoughts or a suicide attempt. • Are allergic to interferons, including interferon alfa-2b, or any ingredient in BESREMi. • Have moderate or severe liver impairment (Child-Pugh B or C). • Have or have had active serious or untreated autoimmune disease. • Are a transplant recipient receiving treatment that suppresses the immune system. BESREMi should also be avoided in people with severe or unstable cardiovascular disease or severe kidney impairment (eGFR below 30 mL/min). People with a history of cardiovascular disease need closer monitoring. Treatment requires monitoring for depression and suicidal thoughts, endocrine disorders, blood cell abnormalities and bleeding, allergic reactions, pancreatitis, colitis, lung problems, eye disorders, raised triglycerides, and liver or kidney damage. Some of these problems may require treatment to be stopped. Significant skin problems may also require stopping treatment. Good oral hygiene and regular dental examinations are advised. BESREMi can harm an unborn baby. People who could become pregnant should use effective contraception. Breastfeeding is not recommended during treatment. Do not drive or use machinery if you experience dizziness, sleepiness or hallucinations.

Interactions

Tell your doctor if you take any of the following: • Medicines processed by CYP450 enzymes that require close control of blood levels. Your doctor may monitor for side effects and adjust the other medicine if needed. • Medicines that suppress blood cell production in the bone marrow. Combining these with BESREMi should be avoided. If used together, monitoring is needed for excessive suppression of blood cell production. • Narcotics, sleeping medicines or sedatives. Combining these with BESREMi should be avoided. If used together, monitoring is needed for excessive effects on the brain and nervous system.

Using BESREMi

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use and how long it may be kept at room temperature afterwards. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label BESREMI (ROPEGINTERFERON ALFA-2B) INJECTION BESREMI PEN (ROPEGINTERFERON ALFA-2B) INJECTION, SOLUTION [PHARMAESSENTIA USA] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines